Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Daclatasvir (Daktavira vs Daklinza) in Healthy Volunteers
NCT02675127Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Dec 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of daclatasvir in hepatitis C (HCV) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration at 72 hours, Area under the plasma concentration-time curve from time zero to the last measurable concentration at 72 hours and 1 more. Started Dec 2015; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02675127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675127.